On March 29, 2024, Charles River Laboratories International, Inc announced that it has received a shareholder proposal from People for the Ethical Treatment of Animals (PETA) requesting Board shall report to shareholders annually on the species, provenance (including country of origin and wild-caught or captive-bred status), and numbers of nonhuman primates imported by our company into the U.S.; the company?s procedures to screen for and report the presence of zoonotic disease among these animals; and measures taken by the company to mitigate the impact of such importation on the dwindling populations of these primates in nature, omitting proprietary information. In addition, the board has recommended shareholders to vote against this proposal at the 2024 Annual Meeting to be held on May 8, 2024.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
231.5 USD | +1.07% | -0.80% | -2.41% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.41% | 11.76B | |
+1.49% | 42.75B | |
+47.70% | 41.61B | |
+12.22% | 41.34B | |
-8.83% | 26.59B | |
+6.68% | 25.49B | |
-23.10% | 18.12B | |
+30.20% | 12.24B | |
+8.65% | 11B | |
-16.49% | 10.07B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc Receives a Shareholder Proposal from People for the Ethical Treatment of Animals